Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. August 2018 06:30 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces that FDA Accepts ELZONRIS™ Biologics License Application (BLA) and Grants Priority Review

Conference call on BLA acceptance and commercial readiness scheduled for Monday, August 13, 2018 at 8:30 AM ET NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:...
09. August 2018 08:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Second Quarter 2018 Financial Results

NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today its...
25. Juni 2018 07:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS™ (tagraxofusp; SL-401) for the Treatment of BPDCN

NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has...
18. Juni 2018 07:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress

NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
15. Juni 2018 08:15 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Presentation of ELZONRIS™ (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress

NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
14. Juni 2018 07:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Three ELZONRIS™ (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress

NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced that ELZONRISTM...
05. Juni 2018 07:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO

NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
18. Mai 2018 07:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress

NEW YORK, May 18, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that SL-401...
17. Mai 2018 07:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting

NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that clinical...
09. Mai 2018 16:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports First Quarter 2018 Financial Results

NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today financial...

Vorherige Seite

Nächste Seite